The Angio-SealTM Closure Device in patients receiving double oral antiplatelet therapy in association with Glycoprotein IIb/IIIa inhibitors has shown positive results. 

The clinical outcome of patients treated with percutaneous coronary interventions (PCI) has dramatically improved over the past years. The two main reasons for this improvement are the use of stents and of more potent antiplatelet agents such as thienopyridines and GP IIb/IIIa receptor blockers. The use of the stents causes more predictable acute results by sealing the dissections created during the inflation of the balloon and thus, reducing in turn the rate of acute complications. Furthermore, stents are more effective in reducing the restenosis rate due to a better acute results and in recent years restenosis rate has been consistently reduced with the advent of drug eluting stents. However, with the use of this new stent platform a double - prolonged antiplatelet therapy is necessary to prevent a catastrophic complication: stent thrombosis. Although more effective antiplatelet agents have dramatically reduced the acute and long-term thrombotic complications especially in high risk subgroups of patients such as those affected by acute coronary syndromes, those beneficial effects are counterbalanced by an increased risk of hemorrhagic complications at the puncture sites combined with more prolonged bed rest,...continua a leggere